Ranibizumab: A Review of Its Use in the Treatment of Neovascular Age-Related Macular Degeneration
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Ranibizumab: A Review of Its Use in the Treatment of Neovascular Age-Related Macular Degeneration
Authors
Keywords
Bevacizumab, Ranibizumab, Aflibercept, Central Retinal Thickness, Pegaptanib
Journal
DRUGS & AGING
Volume 30, Issue 5, Pages 331-358
Publisher
Springer Nature
Online
2013-03-28
DOI
10.1007/s40266-013-0077-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Rate of serious adverse effects in a series of bevacizumab and ranibizumab injections
- (2013) Sanjay Sharma et al. CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
- Intraocular Pharmacokinetics of Ranibizumab Following a Single Intravitreal Injection in Humans
- (2012) Tim U. Krohne et al. AMERICAN JOURNAL OF OPHTHALMOLOGY
- Four-Year Treatment Results of Neovascular Age-Related Macular Degeneration With Ranibizumab and Causes for Discontinuation of Treatment
- (2012) Mads Krüger Falk et al. AMERICAN JOURNAL OF OPHTHALMOLOGY
- Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab
- (2012) Nicholas Papadopoulos et al. ANGIOGENESIS
- Bevacizumab for the Treatment of Neovascular Age-Related Macular Degeneration
- (2012) J. M. Pitlick et al. ANNALS OF PHARMACOTHERAPY
- Measuring the benefit of 4 years of intravitreal ranibizumab treatment for neovascular age-related macular degeneration
- (2012) Sreekumari Pushpoth et al. BRITISH JOURNAL OF OPHTHALMOLOGY
- Cost-Effectiveness Analysis of Ranibizumab versus Verteporfin Photodynamic Therapy, Pegaptanib Sodium, and Best Supportive Care for the Treatment of Age-Related Macular Degeneration in Greece
- (2012) Kostas Athanasakis et al. CLINICAL THERAPEUTICS
- Preferred therapies for neovascular age-related macular degeneration
- (2012) David R. Lally et al. CURRENT OPINION IN OPHTHALMOLOGY
- Ranibizumab
- (2012) James E. Frampton DRUGS
- Aflibercept for Intravitreal Injection
- (2012) James E. Frampton DRUGS & AGING
- Ranibizumab for age-related macular degeneration
- (2012) Dilsher S Dhoot et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Balancing risk in ophthalmic prescribing: assessing the safety of anti-VEGF therapies and the risks associated with unlicensed medicines
- (2012) Peter K. Kaiser et al. GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
- The Expanding Role of Vascular Endothelial Growth Factor Inhibitors in Ophthalmology
- (2012) Michael W. Stewart MAYO CLINIC PROCEEDINGS
- Verteporfin plus Ranibizumab for Choroidal Neovascularization in Age-Related Macular Degeneration
- (2012) Peter K. Kaiser et al. OPHTHALMOLOGY
- HORIZON: An Open-Label Extension Trial of Ranibizumab for Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
- (2012) Michael A. Singer et al. OPHTHALMOLOGY
- Vascular Endothelial Growth Factor in Patients with Exudative Age-related Macular Degeneration Treated with Ranibizumab
- (2012) Philipp S. Muether et al. OPHTHALMOLOGY
- Verteporfin plus Ranibizumab for Choroidal Neovascularization in Age-related Macular Degeneration
- (2012) Michael Larsen et al. OPHTHALMOLOGY
- Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
- (2012) Daniel F. Martin et al. OPHTHALMOLOGY
- Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration
- (2012) Jeffrey S. Heier et al. OPHTHALMOLOGY
- Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration
- (2012) Usha Chakravarthy et al. OPHTHALMOLOGY
- Driving Ability Reported by Neovascular Age-related Macular Degeneration Patients after Treatment with Ranibizumab
- (2012) Neil M. Bressler et al. OPHTHALMOLOGY
- The SECURE Study
- (2012) Rufino Silva et al. OPHTHALMOLOGY
- CEREBROVASCULAR ACCIDENTS IN PATIENTS TREATED FOR CHOROIDAL NEOVASCULARIZATION WITH RANIBIZUMAB IN RANDOMIZED CONTROLLED TRIALS
- (2012) Neil M. Bressler et al. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
- EVEREST STUDY
- (2012) Adrian Koh et al. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
- Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab
- (2011) Ângela M. Carneiro et al. ACTA OPHTHALMOLOGICA
- Estimated Cases of Legal Blindness and Visual Impairment Avoided Using Ranibizumab for Choroidal Neovascularization
- (2011) Neil M. Bressler et al. ARCHIVES OF OPHTHALMOLOGY
- Comparing protein VEGF inhibitors: In vitro biological studies
- (2011) Lanlan Yu et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Systemic Adverse Drug Reactions Secondary to Anti-VEGF Intravitreal Injection in Patients with Neovascular Age-Related Macular Degeneration
- (2011) Francesco Semeraro et al. Current Vascular Pharmacology
- Therapeutic Efficacy of Bevacizumab for Age-Related Macular Degeneration
- (2011) Focke Ziemssen et al. DRUGS & AGING
- Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration
- (2011) NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of a Flexible Dosing Regimen of Ranibizumab in Neovascular Age-Related Macular Degeneration: The SUSTAIN Study
- (2011) Frank G. Holz et al. OPHTHALMOLOGY
- Outcomes and Risk Factors Associated with Endophthalmitis after Intravitreal Injection of Anti-Vascular Endothelial Growth Factor Agents
- (2011) Chirag P. Shah et al. OPHTHALMOLOGY
- Incidence of Retinal Pigment Epithelial Tears after Intravitreal Ranibizumab Injection for Neovascular Age-Related Macular Degeneration
- (2011) Emmett T. Cunningham et al. OPHTHALMOLOGY
- Cost Effectiveness of Treatments for Wet Age-Related Macular Degeneration
- (2011) Paul Mitchell et al. PHARMACOECONOMICS
- Effectiveness at 1 Year of Monthly versus Variable-Dosing Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-related Macular Degeneration
- (2011) Gabriel Katz et al. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
- Effect of Prophylactic Intraocular Pressure–Lowering Medication on Intraocular Pressure Spikes After Intravitreal Injections
- (2010) Max P. C. Frenkel ARCHIVES OF OPHTHALMOLOGY
- Effectiveness of ranibizumab for neovascular age-related macular degeneration using clinician-determined retreatment strategy
- (2010) A. Kumar et al. BRITISH JOURNAL OF OPHTHALMOLOGY
- Effectiveness of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration in a Canadian retina practice: a retrospective review
- (2010) Taha Bandukwala et al. CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
- Cost-effectiveness of ranibizumab for the treatment of neovascular age-related macular degeneration in germany: Model analysis from the perspective of germany's statutory health insurance system
- (2010) Aljoscha S. Neubauer et al. CLINICAL THERAPEUTICS
- Long-term visual course after anti-VEGF therapy for exudative AMD in clinical practice evaluation of the German reinjection scheme
- (2010) Britta Heimes et al. GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
- Cost-utility analysis of bevacizumab versus ranibizumab in neovascular age-related macular degeneration using a Markov model
- (2010) Jignesh J. Patel et al. JOURNAL OF EVALUATION IN CLINICAL PRACTICE
- Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration
- (2010) James C. Folk et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Treat and Extend Regimen Using Ranibizumab for Neovascular Age-Related Macular DegenerationClinical and Economic Impact
- (2010) Omesh P. Gupta et al. OPHTHALMOLOGY
- Efficacy and Safety of Monthly versus Quarterly Ranibizumab Treatment in Neovascular Age-related Macular Degeneration: The EXCITE Study
- (2010) Ursula Schmidt-Erfurth et al. OPHTHALMOLOGY
- ANATOMICAL BENEFIT FROM RANIBIZUMAB TREATMENT OF PREDOMINANTLY CLASSIC NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN THE 2-YEAR ANCHOR STUDY
- (2010) Srinivas R Sadda et al. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
- DOSING REGIMEN AND THE FREQUENCY OF MACULAR HEMORRHAGES IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATED WITH RANIBIZUMAB
- (2010) Irene Barbazetto et al. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
- INJECT AND EXTEND DOSING VERSUS DOSING AS NEEDED
- (2010) Hassiba Oubraham et al. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
- Effects of Ranibizumab in Patients with Subfoveal Choroidal Neovascularization Attributable to Age-related Macular Degeneration
- (2009) Simon P. Rothenbuehler et al. AMERICAN JOURNAL OF OPHTHALMOLOGY
- Improved Vision-Related Function After Ranibizumab vs Photodynamic Therapy
- (2009) Neil M. Bressler ARCHIVES OF OPHTHALMOLOGY
- Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials
- (2009) P Mitchell et al. BRITISH JOURNAL OF OPHTHALMOLOGY
- Ranibizumab for exudative age-related macular degeneration: 24-month outcomes from a single-centre institutional setting
- (2009) G. Querques et al. BRITISH JOURNAL OF OPHTHALMOLOGY
- Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration
- (2009) Luis Javier Hernandez-Pastor et al. CLINICAL THERAPEUTICS
- Off-Label Use of Bevacizumab for the Treatment of Age-Related Macular Degeneration
- (2009) Focke Ziemssen et al. DRUGS & AGING
- Clinical safety of ranibizumab in age-related macular degeneration
- (2009) Ursula Schmidt-Erfurth Expert Opinion On Drug Safety
- Cost-effectiveness of ranibizumab compared with pegaptanib in neovascular age-related macular degeneration
- (2009) Luis Javier Hernández-Pastor et al. GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
- Bevacizumab and ranibizumab on microvascular endothelial cells: A comparative study
- (2009) Raquel Costa et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- A Phase IIIb Study to Evaluate the Safety of Ranibizumab in Subjects with Neovascular Age-related Macular Degeneration
- (2009) David S. Boyer et al. OPHTHALMOLOGY
- SAFETY OF REPEAT INTRAVITREAL INJECTIONS OF BEVACIZUMAB VERSUS RANIBIZUMAB
- (2009) IOANNIS D. LADAS et al. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
- Ranibizumab Combined With Verteporfin Photodynamic Therapy in Neovascular Age-related Macular Degeneration (FOCUS): Year 2 Results
- (2008) Andrew N. Antoszyk et al. AMERICAN JOURNAL OF OPHTHALMOLOGY
- Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-related Macular Degeneration: PIER Study Year 1
- (2008) Carl D. Regillo et al. AMERICAN JOURNAL OF OPHTHALMOLOGY
- Short-term intraocular pressure trends following intravitreal injections of ranibizumab (Lucentis) for the treatment of wet age-related macular degeneration
- (2008) G Mojica et al. BRITISH JOURNAL OF OPHTHALMOLOGY
- Age-related macular degeneration: diagnosis and management
- (2008) H. L. Cook et al. BRITISH MEDICAL BULLETIN
- Neovascular Age-Related Macular Degeneration
- (2008) Aimee V Chappelow et al. DRUGS
- Comparative effects of bevacizumab, ranibizumab and pegaptanib at intravitreal dose range on endothelial cells
- (2008) Ângela Carneiro et al. EXPERIMENTAL EYE RESEARCH
- Cost-effectiveness sequential modeling of ranibizumab versus usual care in age-related macular degeneration
- (2008) S. Y. Cohen et al. GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
- Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study
- (2008) David M. Brown et al. OPHTHALMOLOGY
- INCIDENCE OF ENDOPHTHALMITIS RELATED TO INTRAVITREAL INJECTION OF BEVACIZUMAB AND RANIBIZUMAB
- (2008) DAVID R. FINTAK et al. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started